NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage with an "Outperform" rating and a $6.00 price target. The report reviews the company's lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.
Separately, the company announced that President and Executive Chairman Anil R. Diwan participated in a "Fireside Chat" published by StockInvestor Daily's IPO-Edge program, where he discussed NanoViricides' antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company's regulatory progress, including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox and Ebola. The full press release is available at https://ibn.fm/7XBbY.
NanoViricides is a clinical stage company that creates special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates and technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections.
The lead drug candidate is NV-387, a broad-spectrum antiviral drug planned for treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. Another advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is the nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is another drug candidate for COVID-19 that encapsulates remdesivir within its polymeric micelles. The company believes that since remdesivir is already US FDA approved, the drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead.
NanoViricides is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The company's platform technology and programs are based on the TheraCour nanomedicine technology, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of various human viral diseases.
The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
